Eli Lilly and Co (LLY)
734.97
-20.94
(-2.77%)
USD |
NYSE |
May 03, 16:00
738.49
+3.52
(+0.48%)
After-Hours: 20:00
Eli Lilly Net Income (Quarterly): 2.243B for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 2.243B |
December 31, 2023 | 2.190B |
September 30, 2023 | -57.40M |
June 30, 2023 | 1.763B |
March 31, 2023 | 1.345B |
December 31, 2022 | 1.938B |
September 30, 2022 | 1.452B |
June 30, 2022 | 952.50M |
March 31, 2022 | 1.903B |
December 31, 2021 | 1.726B |
September 30, 2021 | 1.110B |
June 30, 2021 | 1.390B |
March 31, 2021 | 1.355B |
December 31, 2020 | 2.117B |
September 30, 2020 | 1.208B |
June 30, 2020 | 1.412B |
March 31, 2020 | 1.456B |
December 31, 2019 | 1.496B |
September 30, 2019 | 1.254B |
June 30, 2019 | 1.327B |
March 31, 2019 | 4.242B |
December 31, 2018 | 1.125B |
September 30, 2018 | 1.150B |
June 30, 2018 | -259.90M |
March 31, 2018 | 1.217B |
Date | Value |
---|---|
December 31, 2017 | -1.657B |
September 30, 2017 | 555.60M |
June 30, 2017 | 1.008B |
March 31, 2017 | -110.80M |
December 31, 2016 | 771.80M |
September 30, 2016 | 778.00M |
June 30, 2016 | 747.70M |
March 31, 2016 | 440.10M |
December 31, 2015 | 478.40M |
September 30, 2015 | 799.70M |
June 30, 2015 | 600.80M |
March 31, 2015 | 529.50M |
December 31, 2014 | 428.50M |
September 30, 2014 | 500.60M |
June 30, 2014 | 733.50M |
March 31, 2014 | 727.90M |
December 31, 2013 | 727.50M |
September 30, 2013 | 1.203B |
June 30, 2013 | 1.206B |
March 31, 2013 | 1.548B |
December 31, 2012 | 827.30M |
September 30, 2012 | 1.327B |
June 30, 2012 | 923.60M |
March 31, 2012 | 1.011B |
December 31, 2011 | 858.20M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-57.40M
Minimum
Sep 2023
2.243B
Maximum
Mar 2024
1.479B
Average
1.432B
Median
Net Income (Quarterly) Benchmarks
Amgen Inc | -113.00M |
Biogen Inc | 393.40M |
Madrigal Pharmaceuticals Inc | -112.19M |
Vertex Pharmaceuticals Inc | 968.80M |
Viking Therapeutics Inc | -27.36M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 8.768B |
Total Expenses (Quarterly) | 6.032B |
EPS Diluted (Quarterly) | 2.48 |
Enterprise Value | 722.23B |
Gross Profit Margin (Quarterly) | 80.91% |
Profit Margin (Quarterly) | 25.58% |
Earnings Yield | 0.91% |
Operating Earnings Yield | 1.82% |
Normalized Earnings Yield | 1.379 |